logo-loader
viewAstraZeneca

Natixis upgrades AstraZeneca to ‘buy’ on prospect of positive results from key MYSTIC lung cancer trial

The Natixis analysts said: “We expect successful results for MYSTIC, which prompts our target of 5,738p, up from 5,000p previously, but still giving over 25% upside potential”

Clinical trials
However, they added: “If iMYSTIC is a failure, the valuation is 4,304p, which only offers limited downside risk of around 6%”

French broker Natixis has upgraded its rating for AstraZeneca PLC (LON:AZN) to ‘buy’ from ‘neutral’ as its analysts feel the prospect of positive results from the group's key MYSTIC lung cancer trial gives the blue chip drugmaker “an asymmetric risk profile.”

In a note to clients, the analysts said: “We expect successful results for MYSTIC, which prompts our target of 5,738p, up from 5,000p previously, but still giving over 25% upside potential.”

READ: Billions wiped off AstraZeneca’s value as key lung cancer study fails to meet primary endpoint

However, they added: “If iMYSTIC is a failure, the valuation is 4,304p, which only offers limited downside risk of around 6%.”

In late morning trading, AstraZeneca shares were changing hands at 4,535.5p, off 0.8%, or 38p on the day.

The Natixis analysts said: “Our positive scenario draws on an analysis of various lung cancer trials which indicate that a negative PFS (progression-free survival) does not rule out a positive OS (overall survival) result. This could be the case for MYSTIC.”

The analysts said that revenues related to MYSTIC are estimated at US$3.5bn in 2023, with the potential to drive a substantial acceleration in future earnings.

READ: AstraZeneca's share price slump on Mystic trial unwarranted, says investor Neil Woodford

At the end of July, billions were wiped off AstraZeneca’s value as its share price plunged 15% after the much-hyped MYSTIC trial suffered a serious setback.

The Phase III study – which is looking at how two of its lead immune-oncology drugs, Imfinzi and tremelimumab, work together in non-small-cell lung cancer patients – failed to meet the primary endpoint of improving progression-free survival compared to chemotherapy – the current standard of care.

Full data presentations on studies for lung cancer drugs Tagrisso and Imfinzi are expected this month.

Quick facts: AstraZeneca

Price: 6805 GBX

LSE:AZN
Market: LSE
Market Cap: £89.3 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Power Metal Resources 'pushing ahead with key projects' and in strong...

Power Metal Resources Plc's (LON:POW) Paul Johnson tells Proactive London's Andrew Scott they're in an advantageous financial position to deal with the current uncertainty around the coronavirus outbreak. He says they're conducting business diligently, safeguarding existing business...

2 days, 9 hours ago

2 min read